Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01154452CT.gov Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Alveolar Soft Part Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vismodegib (this asset) | National Cancer Institute (NCI) | P1/2 | CCC · 52 |
| Tivantinib | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | P2 | B |
| Crizotinib | European Organisation for Research and Treatment of Cancer - EORTC | P2 | B |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
| Temsirolimus | National Cancer Institute (NCI) | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Zoledronate | University of Florida | P1/2 | CC |
| GVAX | Dana-Farber Cancer Institute | P1 | CC |
| Pimitespib | Taiho Pharmaceutical Co., Ltd. | P1 | CC |
+14 more in the Alveolar Soft Part Sarcoma cohort
Other indications for Vismodegib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2 | BB · 68 |
| Adult Glioblastoma | — | P2 | BB · 65 |
| Malignant Pancreatic Neoplasm | — | P2 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- TivantinibArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)B
- CrizotinibEuropean Organisation for Research and Treatment of Cancer - EORTCB
- CixutumumabNational Cancer Institute (NCI)B
- TemsirolimusNational Cancer Institute (NCI)B
- CabozantinibNational Cancer Institute (NCI)CCC
Citation
Floatz Terminal. Vismodegib in Alveolar Soft Part Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vismodegib-alveolar-soft-part-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →